Le pubblicazioni più impattanti della settimana in 29 specialità, curate dall'IA
Ultimo aggiornamento: 11 mag 2026
Pubblicato: 2026-12-01
Annals of medicine
MediLens Indicizzato: 2026-05-12
This study investigates the variation in ischemic stroke admissions among patients with atrial fibrillation (AF) based on the day of the week. Analyzing data from the nationwide FinACAF study, which included 13,781 patients with a mean age of 79.2 years, the results show significant differences i...
Leggi su PubMedPubblicato: 2026-05-11
Hypertension (Dallas, Tex. : 1979)
MediLens Indicizzato: 2026-05-12
The WISDOM-HMOD study evaluated the relationship between nighttime blood pressure measured by a wrist-type monitor and left ventricular hypertrophy in 1218 patients with hypertension or heart failure. Results showed an average nighttime systolic/diastolic BP of 110.5±13.0/63.5±8.8 mm Hg, with 70....
Leggi su PubMedPubblicato: 2026-05-11
Circulation. Heart failure
MediLens Indicizzato: 2026-05-12
This review addresses the significant advancements in cardiac gene therapy for cardiomyopathy, highlighting the transition of adeno-associated virus-mediated gene replacement into early-phase clinical trials. It notes improvements in biomarkers like NT-proBNP and discusses the challenges in deliv...
Leggi su PubMedPubblicato: 2026-05-11
Medical science monitor : international medical journal of experimental and clinical research
MediLens Indicizzato: 2026-05-12
This study evaluated the impact of a structured, multidisciplinary case management model on cardiac function and glycemic control in elderly patients with coronary heart disease and diabetes undergoing off-pump CABG. A total of 168 patients were randomized to receive either routine care or an enh...
Leggi su PubMedPubblicato: 2026-05-11
Cardiology in review
MediLens Indicizzato: 2026-05-12
This study highlights the critical role of sodium-glucose cotransporter 2 inhibitors and nonsteroidal mineralocorticoid receptor antagonists in reducing cardiovascular and kidney disease risks in patients with type 2 diabetes. Empagliflozin showed significant benefits in reducing cardiovascular m...
Leggi su PubMedMedici di tutto il mondo iniziano la giornata con revisioni della letteratura curate dall'IA, consegnate alle 7.
Prova gratuita di 14 giorni